Showing 1 posts of 1 posts found.
Savient Pharmaceuticals has reported that some production batches of Krystexxa, its recently-approved second-line treatment for gout, have failed to meet …
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease